Sand Hill Global Advisors LLC Sells 1,033 Shares of Gilead Sciences, Inc. (GILD)
Sand Hill Global Advisors LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 77,117 shares of the biopharmaceutical company’s stock after selling 1,033 shares during the quarter. Sand Hill Global Advisors LLC’s holdings in Gilead Sciences were worth $5,458,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Meridian Investment Counsel Inc. raised its position in shares of Gilead Sciences by 95.5% in the first quarter. Meridian Investment Counsel Inc. now owns 19,101 shares of the biopharmaceutical company’s stock valued at $1,297,000 after purchasing an additional 9,330 shares during the period. NewFocus Financial Group LLC bought a new position in shares of Gilead Sciences in the first quarter valued at approximately $428,000. Edmonds Duncan Registered Investment Advisors LLC raised its position in shares of Gilead Sciences by 3.3% in the first quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $429,000 after purchasing an additional 200 shares during the period. Van Strum & Towne Inc. raised its position in shares of Gilead Sciences by 48.1% in the first quarter. Van Strum & Towne Inc. now owns 52,025 shares of the biopharmaceutical company’s stock valued at $3,534,000 after purchasing an additional 16,898 shares during the period. Finally, Hourglass Capital LLC raised its position in shares of Gilead Sciences by 10.5% in the first quarter. Hourglass Capital LLC now owns 119,647 shares of the biopharmaceutical company’s stock valued at $8,126,000 after purchasing an additional 11,389 shares during the period. 74.62% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $71.81 on Thursday. The stock has a market capitalization of $92,941.05, a price-to-earnings ratio of 7.43, a price-to-earnings-growth ratio of -1.19 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue was down 13.2% on a year-over-year basis. During the same period last year, the business earned $2.75 earnings per share. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.90%. Gilead Sciences’s payout ratio is presently 23.69%.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. Over the last three months, insiders have sold 666,819 shares of company stock valued at $52,303,086. Company insiders own 1.30% of the company’s stock.
GILD has been the topic of a number of recent analyst reports. BMO Capital Markets reissued a “hold” rating and issued a $72.00 price target on shares of Gilead Sciences in a research report on Friday, July 21st. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Leerink Swann restated a “hold” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 25th. Robert W. Baird restated an “outperform” rating and issued a $87.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 25th. Finally, Redburn Partners began coverage on shares of Gilead Sciences in a research note on Wednesday, July 26th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $84.87.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/sand-hill-global-advisors-llc-sells-1033-shares-of-gilead-sciences-inc-gild/1706239.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.